NASDAQ:DTIL Precision BioSciences (DTIL) Stock Forecast, Price & News $0.38 +0.01 (+1.76%) (As of 12:45 PM ET) Add Compare Share Share Today's Range$0.36▼$0.3850-Day Range$0.37▼$0.6652-Week Range$0.35▼$1.70Volume241,112 shsAverage Volume788,739 shsMarket Capitalization$43.19 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Precision BioSciences MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside699.4% Upside$3.00 Price TargetShort InterestHealthy1.82% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.27Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.77) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector396th out of 961 stocksBiological Products, Except Diagnostic Industry62nd out of 161 stocks 3.3 Analyst's Opinion Consensus RatingPrecision BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Precision BioSciences has a forecasted upside of 699.4% from its current price of $0.38.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.82% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precision BioSciences has recently increased by 62.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecision BioSciences has received a 72.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Precision BioSciences is -0.99. Previous Next 2.4 News and Social Media Coverage News SentimentPrecision BioSciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Precision BioSciences this week, compared to 6 articles on an average week.Search Interest10 people have searched for DTIL on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows8 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($0.77) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Precision BioSciences (NASDAQ:DTIL) StockPrecision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More DTIL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DTIL Stock News HeadlinesSeptember 24, 2023 | tmcnet.comVial to Sponsor the 21st Precision in Clinical Trials Summit 2023 in San Diego, CASeptember 20, 2023 | americanbankingnews.comPrecision BioSciences' (DTIL) Buy Rating Reaffirmed at HC WainwrightSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 19, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Precision BioSciencesSeptember 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Precision BioSciences (DTIL)September 16, 2023 | finance.yahoo.comThis Precision BioSciences Insider Increased Their Holding By 38% Last YearSeptember 15, 2023 | tmcnet.comPrecision Dropper - The Next Revolution in Eye HealthSeptember 15, 2023 | businesswire.comGlobal Precision Fermentation Ingredients Market: Explosive Growth with 44.0% CAGR, Reaching $36.3 Billion by 2030 - ResearchAndMarkets.comSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 13, 2023 | markets.businessinsider.comBTIG Sticks to Their Buy Rating for Precision BioSciences (DTIL)September 12, 2023 | finance.yahoo.comPrecision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program DevelopmentsSeptember 8, 2023 | msn.comRatnaveer Precision Engineering shares to list on September 11, marking the first T+3 debutSeptember 8, 2023 | msn.comRatnaveer Precision IPO allotment – how to check allotment, GMP, listing date and moreSeptember 7, 2023 | marketwatch.comPrecision Drilling to Acquire CWC Energy Services in C$141M DealSeptember 6, 2023 | bizjournals.comAbrasive Technologies acquires Cincinnati machining, mining company Swiss PrecisionSeptember 6, 2023 | finance.yahoo.comPrecision BioSciences to Attend and Present at Upcoming September Investor ConferencesSeptember 6, 2023 | msn.comRatnaveer Precision Engineering IPO subscribed 42 times on Day 3 so farSeptember 5, 2023 | msn.comRatnaveer Precision Engineering IPO subscribed nearly 16x so far on Day 2. Check GMP and other detailsSeptember 4, 2023 | msn.comRatnaveer Precision Engineering IPO subscribed 5.7x on day 1September 4, 2023 | msn.comRatnaveer Precision Engineering Limited IPO Subscribed Fully On First Day; Check GMP, Price, Allotment Date, MoreAugust 31, 2023 | finance.yahoo.comPrecision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023August 30, 2023 | msn.comRatnaveer Precision Engineering IPO to open on September 4: Check price band & other detailsAugust 23, 2023 | technews.tmcnet.comPrecision Farming Market worth $21.9 billion by 2031 - Exclusive Report by MarketsandMarkets™August 22, 2023 | finance.yahoo.comWhy Durham biotech's pivot means smaller, leaner companyAugust 18, 2023 | msn.comDynalife ownership to transfer all staff, operations, physical labs to Alberta Precision LabsAugust 18, 2023 | finance.yahoo.comAfter Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)August 17, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Precision BioSciencesSee More Headlines Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address DTIL Company Calendar Last Earnings8/04/2023Today9/26/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DTIL CUSIPN/A CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees192Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+699.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,640,000.00 Net Margins-192.10% Pretax Margin-192.10% Return on Equity-163.24% Return on Assets-39.90% Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.62 Sales & Book Value Annual Sales$25.10 million Price / Sales1.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book0.70Miscellaneous Outstanding Shares115,070,000Free Float110,468,000Market Cap$43.19 million OptionableNot Optionable Beta1.31 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael Amoroso (Age 45)Pres, CEO & Director Comp: $979.04kMr. John Alexander Kelly R.Ph. (Age 56)Chief Financial Officer Comp: $623.58kMr. Dario Scimeca (Age 47)Gen. Counsel & Sec. Comp: $576.43kDr. Derek Jantz Ph.D. (Age 47)Co-Founder & Chief Science Advisor Dr. Jefferson J. Smith Ph.D. (Age 50)Co-Founder & Chief Research Officer Mr. Shane Barton (Age 52)VP, Corp. Controller & Principal Accounting Officer Mei BurrisDirector of Investor Relations & Fin.Mr. Bruce StevensVP of Quality & ComplianceMaurissa MessierSr. Director of Corp. CommunicationsMs. Juli BlancheChief People OfficerMore ExecutivesKey CompetitorsOKYO PharmaNASDAQ:OKYOBrainstorm Cell TherapeuticsNASDAQ:BCLICurisNASDAQ:CRISQuince TherapeuticsNASDAQ:QNCXMiNK TherapeuticsNASDAQ:INKTView All CompetitorsInsiders & InstitutionsCHI Advisors LLCSold 1,866,263 shares on 8/22/2023Ownership: 1.394%Stifel Financial CorpBought 1,049,771 shares on 8/15/2023Ownership: 1.702%Goldman Sachs Group Inc.Bought 49,664 shares on 8/15/2023Ownership: 0.144%Captrust Financial AdvisorsSold 28,194 shares on 8/15/2023Ownership: 0.107%Citadel Advisors LLCSold 9,000 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions DTIL Stock - Frequently Asked Questions Should I buy or sell Precision BioSciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DTIL shares. View DTIL analyst ratings or view top-rated stocks. What is Precision BioSciences' stock price forecast for 2023? 3 brokerages have issued 12-month price targets for Precision BioSciences' stock. Their DTIL share price forecasts range from $2.00 to $4.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 699.4% from the stock's current price. View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts. How have DTIL shares performed in 2023? Precision BioSciences' stock was trading at $1.19 at the beginning of the year. Since then, DTIL shares have decreased by 68.5% and is now trading at $0.3753. View the best growth stocks for 2023 here. Are investors shorting Precision BioSciences? Precision BioSciences saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,640,000 shares, an increase of 62.4% from the August 15th total of 1,010,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 1.5 days. Approximately 1.8% of the company's shares are short sold. View Precision BioSciences' Short Interest. When is Precision BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our DTIL earnings forecast. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) issued its earnings results on Friday, August, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.13. The company had revenue of $19.79 million for the quarter, compared to analyst estimates of $6.58 million. Precision BioSciences had a negative trailing twelve-month return on equity of 163.24% and a negative net margin of 192.10%. What ETF holds Precision BioSciences' stock ? Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio. What is Matt Kane's approval rating as Precision BioSciences' CEO? 12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA). When did Precision BioSciences IPO? (DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO. What is Precision BioSciences' stock symbol? Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL." Who are Precision BioSciences' major shareholders? Precision BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Great Point Partners LLC (6.49%), JPMorgan Chase & Co. (1.81%), Stifel Financial Corp (1.70%), Renaissance Technologies LLC (1.49%), CHI Advisors LLC (1.39%) and BlackRock Inc. (1.06%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane, Michael Amoroso and Vince Craig Hopkin. View institutional ownership trends. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Precision BioSciences' stock price today? One share of DTIL stock can currently be purchased for approximately $0.38. How much money does Precision BioSciences make? Precision BioSciences (NASDAQ:DTIL) has a market capitalization of $43.19 million and generates $25.10 million in revenue each year. The company earns $-111,640,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. How many employees does Precision BioSciences have? The company employs 192 workers across the globe. How can I contact Precision BioSciences? Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The official website for the company is www.precisionbiosciences.com. The company can be reached via phone at (919) 314-5512 or via email at jwong@bplifescience.com. This page (NASDAQ:DTIL) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.